Menu Menu Menu
Nice Insight Research
Content Menu
Menu Menu Menu
To Top

Search By Topic

Formulation

69 Articles available
Collaboration

Context Therapeutics Signs Strategic Research Collaborations for Apristor® (onapristone extended release) With Key Academic Leaders in the Progesterone Receptor (PR) and Breast Cancer Fields

PR-M08-18-NI-086
Supply Chain

Building a Robust Supply Chain with Dependable Quality Primary Suppliers

PAO-M07-18-CL-001
Clinical Data

Pulmatrix Announces Positive Top-Line Preliminary Results from Part 3 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole

PR-M07-18-NI-058
Equipment Selection

Tackling Powder Flow Problems by Choosing the Right Equipment

PAO-05-18-CL-007
OSD Facility Design

Modern OSD Facility Design Considerations for Operational Efficiency and Regulatory Compliance

PAP-Q2-18-CL-012
Controlled Nucleation

Achieving Controlled Nucleation During Aseptic Lyophilization

PAP-Q2-18-CL-018
Formulation

Differentiating Generic SODFs with Hard Capsule Formulations

PAO-Q1-18-CL-004
Collaboration

Xeris Pharmaceuticals Announces a Formulation Development Collaboration with Asahi Kasei Pharma

PR-M03-18-NI-061
Capsules

Overcoming Formulation Challenges with Liquid-fill Capsules

PAP-Q1-18-CL-004
Formulation

Investing in New Technologies for Innovative Functional Solutions

PAP-Q1-18-CL-009
Opadry System

Colorcon, Inc. Transforms the Sugar Coating Process with a New Opadry System

PR-M01-18-NI-071
Launch

DSM Sinochem Pharmaceuticals successfully launches Rosuvastatin finished dosage formulation in Western Europe

PR-M01-18-NI-054
Innovation

Single-Pill, HIV-1 Combination Therapy Approved

PAO-M11-17-NI-050
Discovery

Boehringer Ingelheim and HitGen Enter Drug Discovery Collaboration

PAO-M11-17-NI-049
Acquisition

Almac Expands Analytical Services with BioClin Laboratories Acquisition

PAO-M11-17-NI-033
Drug Development

Small Molecule Cancer Combination Therapy Receives Second Patent

PAO-M11-17-NI-031
Topical

New NSAID Topical Gels Penetrate Three Times Faster

PAO-M11-17-NI-004
Drug Delivery

Subdermal Parkinson’s Implant Treatment in Trials

PAO-M10-17-NI-024
Formulation

Polyphor AG: Polyphor Launches the Development of an Inhaled Formulation of its Antibiotic Murepavadin

PR-M10-17-NI-004
Innovation

Bone Marrow Transplant Therapy Gets Monoclonal Antibody Boost

PAO-M10-17-NI-015
Drug Development

New Insulin Formulation Improves Mealtime Glycemic Control

PAO-M10-17-NI-011
Drug Development

Biotechs Collaborate to Develop Multifunctional Cancer Immunotherapies

PAO-M10-17-NI-009
Formulation

DNA Binding Protein May Increase Ovarian Cancer Survival

PAO-M09-17-NI-034
FDA Approval

FDA Approves Grifols’ Prolastin-C Liquid

PAO-M09-17-NI-032
Abuse Deterrence

Fighting Prescription Drug Abuse with Demonstrated Abuse-Deterrent Formulations

PAP-Q3-17-CL-003
Continuous Manufacturing

Innovation and Formulation

Thomas Hofmaier, Head of Business Unit Process Technology Pharma, Glatt Air Techniques

PTV-M03-17-IN-005
CDMO

Topical Drug Formulations – Strong Growth Based on New Understandings: Q&A with BASF Pharma Solutions

PAO-M04-17-NI-014
Excipients

Making it Simple

Ken Seufert, Managing Director, Meggle USA

PTV-M11-16-AP-030
Formulation

Focusing on Patient Compliance

Brian Wilson, Technical Development Manager, SPI Pharma

PTV-M01-17-NS-011
Formulation

Partnering for Formulation Development

Elsie Melsopp, Director of Formulation, Alcami

PTV-M11-16-AP-001
Formulation

Innovative Drug Delivery Technology

Kevin Haehl, General Manager, North America, Unither Pharmaceuticals

PTV-M11-16-AP-006
CDMO

Choosing the Right Pathway

Ken Phelps, President & CEO, Camargo

PTV-M11-16-AP-007
CDMO

Servier Offers Quality Service

Gwenael Servant, Managing Director, Servier CDMO

PTV-M11-16-AP-012
Formulation

Enhancement and Availability

Edward Rudnic, CEO, Dispersol

PTV-M11-16-AP-015
Equipment

Freund Vector Can’t Go Wrong with Granurex

Shawn Engels, Senior Process Development Engineer, Freund Vector

PTV-M11-16-AP-017
Formulation

Expanding Capabilities

Frank Sorce, Vice President of Business Development, UPM Pharmaceuticals

PTV-M11-16-AP-023
CDMO

Understanding Solid State Properties for Formulation Success

PAO-M04-17-NI-001
API

Energizing Client Portfolios with Patient-Friendly Dosage Forms

PAP-Q1-17-CL-001
Excipients

Spending on Excipients Grows & Diversifies

PAP-Q1-17-FA-004
CDMO

Operational Excellence in Outsourced Fill-Finish Services

PAP-Q1-17-IC-001
API

Expanding the Commercial Options for Preparation of Amorphous Solid Dispersions

PAP-Q1-17-CL-006
API

Particle Engineering for Improved Bioavailability in Oral Solid Dose Medications

PAP-Q1-17-CL-014
API

Next-Generation OSD Manufacturing Strategy

PAP-Q1-17-CL-015
CDMO

Enhancing Responsiveness with Embedded Flexibility

PAP-Q1-17-CL-008
Equipment

An OEE Approach To Solid Dose Equipment Purchasing and Implementation

PAP-Q1-17-CL-005
Formulation

Pharmapack 2017: Innovations in Medical Devices

PAO-M02-17-NI-001
Excipients

What’s New at AAPS: Materials

PAP-M11-16-NI-001
API

Two Promising Small-Molecule Orphan Drugs in Clinical Trials

PAP-Q04-16-TT-001
API

A New Industry Think Tank Forum for Leaders of Outsourced Services and Customers

PAP-Q04-16-NS-001
API

Designing Effective Drug Formulations: Keys to Successful Proof of Concept Services

PAP-Q04-16-CL-004
Formulation

Better Design, Better Outcomes, Better Economics

PAP-Q04-16-IL-001
API

Dry-Powder Inhalation Formulation: Balancing Performance and Manufacturability

PAP-Q04-16-CL-006
API

Future Pharma Partner Models: Pharma 3.0

PAP-Q03-16-FA-001
API

Embracing Formulation Expertise to Extend Exclusivity & Improve the Patient Experience

PAP-Q03-16-CL-005
API

Accelerating Approval and Reducing Costs of Spray Dried Drugs through Development by Design (DbD)

PAP-Q03-16-CL-011
API

Biocatalysis Versus Chemocatalysis

MCP-M04-16-NI-001
CDMO

From Qualified to Ideal: The Importance of Partnership

PAP-Q02-16-VP-001
Excipients

Optimising Excipients to Improve Bioavailability

MCP-M03-16-NI-001
API

Formulation Challenges Drive Interest in CDMOS

MCP-M01-16-NI-001
API

In-depth Process and Product Expertise – This is Key to CDMO Support of Orphan Drug and Breakthrough Therapy Development & Commercialization

PAP-Q4-15-CL-004
Formulation

Choosing the Optimal Drug Delivery System to Meet Patient Needs

PAP-Q4-15-CL-008
Outsourcing

CRO or CMO: Which Is Best For Your Preformulation Needs?

LSL-M05-15-NI-001
Excipients

Speaking the Same Language – The Gap Between the Sales Pitch and Supplier Selection Criteria – And How It Applies in the Excipients Market

APR-M03-15-NI-004
Equipment

Trends In Outsourcing – The Benefit Of Engaging A CMO For Injectable Product Development Through To Fill Finish

MCP-M03-15-NI-002
CDMO

New Technologies In Fill-Finish May Bring Brand Loyalty Along with Improved Patient Safety

LSL-M04-14-NI-001
Outsourcing

Trends In Outsourcing — What’s Going On In Big Pharma

LSL-M06-13-NI-001
Formulation

Outsourcing and the Oral Solid Dose: Will Challenges Lead to New Patterns of Outsourcing?

CIO-M06-13-NI-001
Outsourcing

The Right Preformulation / Formulation Outsourcing Partner Can Alleviate Challenges To Reducing Costs

CIO-M09-12-NI-001
CDMO

Customer Drivers Influencing Supplier Differentiation

PTO-M08-11-NI-001
×